Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new ziac research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on ziac
A continuum-based outcome approach to measuring performance in HIV/AIDS case management.
AIDS Care. 2007 Jul; 19(6): 767-74
Gimbel R, Ziac V, Tackley L, Lehrman S, Freedman J
This methods paper is third in a series addressing client outcomes in HIV/AIDS case management. After introducing earlier work the authors outline their effort to consolidate numerous discrete outcome measures and to establish each outcome indicator along a continuum scale that can be self-abstracted by HIV/AIDS service providers. The paper includes in-depth discussion of challenges and benefits derived from this type of outcome measurement process. Key lessons learned from a pilot study are offered for those considering development of similar client outcomes assessment programmes. The paper concludes with several opportunities for future research for those desiring to work in this relatively uncharted domain.
Am J Hypertens. 2001 Aug; 14(8 Pt 1): 783-7
Sorof JM, Urbina EM, Cunningham RJ, Hogg RJ, Moxey-Mims M, Eissa MA, Rolf C,
BACKGROUND: The FDA Modernization Act has resulted in an increase in pediatric trials of antihypertensive medications. As experience is limited in children to guide the planning of these studies, we reviewed data from the Ziac Pediatric Hypertension Study to determine patterns of early study termination to help future studies. METHODS: For inclusion, subjects aged 6 to 17 years were required to have an average systolic blood pressure (SBP) or diastolic blood pressure (DBP) above the 95th percentile at the last of three visits during 2 weeks of single-blind placebo screening. Early study termination was defined as early termination for any reason. Screening termination was defined as normalization of blood pressure (BP) during the placebo screening phase. RESULTS: Early study termination rate was 27% (38 of 140 subjects). The most common reason was screening termination due to normalization of BP, accounting for 63% of all early study terminations. Among screening termination subjects who completed three screening visits, SBP was higher (P < .001) at visit 1 (129+/-8 mm Hg) than at visit 2 (123+/-7 mm Hg) or visit 3 (121+/-8 mm Hg), but did not differ between visits 2 and 3. Screening termination occurred in 15% with isolated SBP hypertension, and 21% with isolated DBP hypertension. At randomization, 83% had SBP hypertension and 53% had DBP hypertension. CONCLUSIONS: These data suggest that SBP hypertension should be part of inclusion criteria to increase enrollment and reduce the rate of screening termination, and that 1-week placebo screening is necessary and sufficient to minimize inclusion of transiently hypertensive subjects.
The role of combination therapy in the treatment of hypertension.
Am J Hypertens. 1998 Jun; 11(6 Pt 2): 73S-78S; discussion 95S-100S
Moser M, Black HR
Only approximately 40% to 50% of hypertensive patients will achieve goal blood pressures of
Rev Med Liege. 1996 May; 51(5): 382-4
Kulbertus H
DOs encouraged to participate in pharmaceutical, clinical trials.
J Am Osteopath Assoc. 1994 May; 94(5): 378
Allen TW
Med Lett Drugs Ther. 1994 Mar 18; 36(918): 23-4